These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1781971)

  • 1. Clinical issues of cognitive enhancers in Alzheimer disease.
    Calvani M; Carta A
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S25-31. PubMed ID: 1781971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current clinical trials of cognitive enhancers in Japan.
    Shimizu M
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S13-24. PubMed ID: 1781970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive enhancing agents: current status in the treatment of Alzheimer's disease.
    Waters C
    Can J Neurol Sci; 1988 Aug; 15(3):249-56. PubMed ID: 3061625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment issues in clinical trials of tetrahydroaminoacridine and studies to alter decline in Alzheimer disease.
    Thal LJ
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S37-9. PubMed ID: 1781972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metrifonate for Alzheimer's disease patients.
    Schneider LS
    J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
    [No Abstract]   [Full Text] [Related]  

  • 6. [Viewpoint on the methodology of drug trials affecting cognition of elderly patients].
    Allain H; Bernard PM; Dartigues JF; Dérouesné C; Dubois B; Hugonot L; Laurent B; Léger JM; Malauzat D; Michel B
    Encephale; 1994; 20(6):725-39. PubMed ID: 7875107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
    Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
    J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive outcome measures.
    Ferris SH
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S140-2. PubMed ID: 10609693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Amaducci L; Baldereschi M; Doody R; Chandra V; Gaines AD
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():19-21. PubMed ID: 9305509
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial design issues in mild to moderate Alzheimer disease.
    Knopman DS
    Cogn Behav Neurol; 2008 Dec; 21(4):197-201. PubMed ID: 19057167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dementia. Diagnostic problems].
    Derouesné C
    Therapie; 1993; 48(3):189-93. PubMed ID: 8140556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary communication. A double-blind placebo-controlled trial of L-tryptophan to assess the degree of cognitive and behavioural improvement in patients with Alzheimer-type dementia and to compare differential response in clinical sub-groups.
    Bentham PW
    Int Clin Psychopharmacol; 1990 Oct; 5(4):261-72. PubMed ID: 2081897
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.
    Oken BS; Storzbach DM; Kaye JA
    Arch Neurol; 1998 Nov; 55(11):1409-15. PubMed ID: 9823823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new approach to the measurement of cognitive deficits in dementia.
    Christensen KJ
    Clin Geriatr Med; 1989 Aug; 5(3):519-30. PubMed ID: 2680031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Dementia Rating (CDR).
    Berg L
    Psychopharmacol Bull; 1988; 24(4):637-9. PubMed ID: 3249765
    [No Abstract]   [Full Text] [Related]  

  • 18. Citicoline in vascular cognitive impairment and vascular dementia after stroke.
    Alvarez-Sabín J; Román GC
    Stroke; 2011 Jan; 42(1 Suppl):S40-3. PubMed ID: 21164117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: protocol for a randomized controlled trial.
    Chua KK; Wong A; Kwan PW; Song JX; Chen LL; Chan AL; Lu JH; Mok V; Li M
    Trials; 2015 Apr; 16():199. PubMed ID: 25925312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.